Lytix Biopharma
Lytix Biopharma: Redeye Resumes Coverage (Redeye)
2024-04-26 15:08
Through the completion of the equity issue, Lytix receives NOK50m before transaction costs. The issue was almost fully subscribed to the lower amount, with around 5% going to certain pre-committing shareholders and guarantors.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se